Published in Biochem J on February 01, 1993
Development of an affinity silica monolith containing alpha1-acid glycoprotein for chiral separations. J Chromatogr A (2007) 0.95
Mechanism of ligand binding to alpha 1-acid glycoprotein (orosomucoid): correlated thermodynamic factors and molecular parameters of polarity. Biochem J (1995) 0.76
On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography. Anal Bioanal Chem (2016) 0.75
Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev (1988) 2.57
Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein. Biochem Pharmacol (1982) 1.29
Steroid-protein interactions. XXXIV. Chemical modification of alpha1-acid glycoprotein for characterization of the progesterone binding site. Biochim Biophys Acta (1976) 1.04
Fluorescence quenching of human orosomucoid. Accessibility to drugs and small quenching agents. Biochem J (1985) 0.96
pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid). Biochem J (1991) 0.94
The binding of aryl carboxylic acid derivatives to human serum albumin--a structure-activity study. Biochem Pharmacol (1984) 0.92
Fluorescent investigations of binding of phenprocoumon to alpha 1-acid glycoprotein. J Pharm Sci (1987) 0.85
Signs of the times: the need for a stereochemically informative generic name system. Trends Pharmacol Sci (1989) 2.67
In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol (2007) 1.78
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol (2007) 1.77
Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol (1982) 1.65
Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci (1984) 1.54
Inhibitors of Cytochrome P-450s and their mechanism of action. Drug Metab Rev (1981) 1.42
Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf (1998) 1.39
Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem (2001) 1.35
Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochem Pharmacol (1994) 1.35
Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem (1992) 1.32
Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein. Biochem Pharmacol (1982) 1.29
One-wedge convention for stereochemical representations. Enantiomer (2000) 1.27
Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res (1999) 1.26
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol (1984) 1.24
Clofibrate and enzymatic induction in man. Int J Clin Pharmacol Biopharm (1978) 1.18
Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology (1990) 1.13
Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem (1985) 1.11
Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet (1994) 1.11
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem (1991) 1.09
Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs (1996) 1.08
Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem (2000) 1.07
[Sinus bradycardia and sinoauricular block induced by carbamazepine]. Presse Med (1983) 1.07
Theoretical conformational studies on some dopamine antagonistic benzamide drugs: 3-pyrrolidyl- and 4-piperidyl derivatives. J Med Chem (1983) 1.06
Influence of sex on drug kinetics in man. Clin Pharmacokinet (1977) 1.06
Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell Mol Life Sci (2002) 1.05
The distribution of bound propranolol between the different human serum proteins. Mol Pharmacol (1980) 1.05
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem (1993) 1.05
Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol (1984) 1.04
Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol (1998) 1.03
Molecular lipophilicity potential, a tool in 3D QSAR: method and applications. J Comput Aided Mol Des (1994) 1.01
Diseases and drug protein binding. Clin Pharmacokinet (1978) 1.01
Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React (1996) 1.00
Structural damage to proteins caused by free radicals: asessment, protection by antioxidants, and influence of protein binding. Biochem Pharmacol (2001) 1.00
Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin. Clin Pharmacol Ther (1986) 1.00
The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. Mol Pharmacol (1986) 0.99
X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore. J Med Chem (1995) 0.99
Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters. Eur J Clin Pharmacol (1974) 0.98
Critical risk/benefit analysis of pefloxacine use in children under 15 years--the problem of arthralgias. Int J Clin Pharmacol Ther Toxicol (1987) 0.97
Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol (1998) 0.97
Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol (1993) 0.96
Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J Med Chem (2000) 0.95
Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol (1999) 0.95
pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid). Biochem J (1991) 0.94
Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion. Ther Drug Monit (1983) 0.94
Partitioning of solutes in different solvent systems: the contribution of hydrogen-bonding capacity and polarity. J Pharm Sci (1991) 0.93
A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm (1987) 0.93
Diclofenac binding to albumin and lipoproteins in human serum. Biochem Pharmacol (1985) 0.92
The binding of aryl carboxylic acid derivatives to human serum albumin--a structure-activity study. Biochem Pharmacol (1984) 0.92
In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Res (2001) 0.92
Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit (1988) 0.92
Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol (1998) 0.92
In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Invest New Drugs (2000) 0.91
New insights into the second generation antihistamines. Drugs (2001) 0.91
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I). Clin Pharmacokinet (1990) 0.91
Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res (1996) 0.91
Metabolic chiral inversion of ibuprofen in isolated rat hepatocytes. Chirality (1990) 0.91
Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. Drug Metab Dispos (2000) 0.90
Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation. FEBS Lett (2001) 0.89
Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study. Br J Clin Pharmacol (2001) 0.89
Binding of 8-methoxypsoralen to human serum proteins and red blood cells. Br J Dermatol (1987) 0.89
The influence of stereochemical factors on drug disposition. Drug Metab Rev (1973) 0.89
Tacrolimus decreases in vitro oxidative phosphorylation of mitochondria from rat forebrain. Life Sci (1998) 0.89
Trimetazidine reduces renal dysfunction by limiting the cold ischemia/reperfusion injury in autotransplanted pig kidneys. J Am Soc Nephrol (2000) 0.88
Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther (1998) 0.88
Separation procedures used to reveal and follow drug-protein binding. J Chromatogr (1990) 0.87
Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharmacol Res (1983) 0.87
A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man. Eur J Clin Pharmacol (1975) 0.87
Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants. Free Radic Biol Med (1998) 0.87
In vitro studies on the distribution of probucol among human plasma lipoproteins. Mol Pharmacol (1984) 0.87
Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol (1987) 0.87
Dehydroepiandrosterone and alpha-estradiol limit the functional alterations of rat brain mitochondria submitted to different experimental stresses. Neuroscience (2002) 0.86
Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int J Clin Pharmacol Ther Toxicol (1993) 0.86
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem (2000) 0.86
Serotonin enhances the beta-adrenergic response in rat brain cortical slices. Eur J Pharmacol (1992) 0.86
Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes. Biochem Pharmacol (1992) 0.86
Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol (1996) 0.86
Effects of trimetazidine on lipid peroxidation and phosphorus metabolites during cold storage and reperfusion of isolated perfused rat kidneys. J Pharmacol Exp Ther (1998) 0.86
Multiple human serum binding of two thienopyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, alpha1-acid glycoprotein and lipoproteins. Biochem Pharmacol (1982) 0.85
Substituted xanthones as selective and reversible monoamine oxidase A (MAO-A) inhibitors. Pharm Res (1993) 0.85
Mechanisms of liposomes/water partitioning of (p-methylbenzyl)alkylamines. Pharm Res (1998) 0.85
Circular dichroic determination of the preferred conformation of nicotine and related chiral alkaloids in aqueous solution. Mol Pharmacol (1973) 0.85
In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res (1986) 0.85
Study of the expression of the genetic variants of human alpha1-acid glycoprotein in healthy subjects using isoelectric focusing and immunoblotting. J Chromatogr B Biomed Sci Appl (1998) 0.85
Glucocorticoids decrease cytochrome c oxidase activity of isolated rat kidney mitochondria. FEBS Lett (1998) 0.85
Effect of phenylbutazone on the binding of vitamin K antagonists to albumin. Eur J Clin Pharmacol (1973) 0.85
Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat. J Pharmacol Exp Ther (1990) 0.84
Bicarbonate-catalyzed hydrolysis of hexamethylene diisocyanate to 1,6-diaminohexane. Toxicol Lett (1991) 0.84
Role of bilirubin in the regulation of the total peroxyl radical trapping antioxidant activity of plasma in sickle cell disease. Biochem Biophys Res Commun (1998) 0.84
The binding characteristics of some adrenergic beta-receptor antagonists to human serum proteins. Biochem Pharmacol (1982) 0.84
Familial laryngeal abductor paralysis with presumed autosomal dominant inheritance. Ann Otol Rhinol Laryngol (1982) 0.84
Comparative study of bepridil and nicardipine action on respiration and calcium transport in mitochondria. Int J Clin Pharmacol Ther Toxicol (1987) 0.84
An antifungal gamma-pyrone and xanthones with monoamine oxidase inhibitory activity from Hypericum brasiliense. Phytochemistry (1994) 0.84